Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
(PRISMM Trial)
Recruiting in Palo Alto (17 mi)
Overseen ByCesar Santa-Maria, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
No Placebo Group
Approved in 3 jurisdictions
Trial Summary
What is the purpose of this trial?This study is being done to see if patients with metastatic solid tumors (hematologic malignancies and lymphoma excluded) who have a specific genetic mutation in patients' tumor (the SF3B1, U2AF1 or SRSF2 mutation), are more likely to respond to immunotherapy agents that are now commercially available.
Eligibility Criteria
Inclusion Criteria
Performance status eligible for immune checkpoint blockade as determined by local physician
Able to demonstrate histologically proven locally advanced or metastatic solid tumors (hematologic malignancies and lymphoma excluded)
genomic testing demonstrating a spliceosome mutation (SF3B1, U2AF1 or SRSF2)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Patients with SF3B1, U2AF1 or SRSF2 mutationExperimental Treatment1 Intervention
Metastatic solid tumor patients that have a SF3B1, U2AF1 or SRSF2 mutation
Immunotherapy is already approved in European Union, United States, Canada for the following indications:
🇪🇺 Approved in European Union as Various Immunotherapies for:
- Melanoma
- Non-Hodgkin lymphoma
- Chronic myelogenous leukemia (CML)
- Kidney cancer
- Breast cancer
- Prostate cancer
🇺🇸 Approved in United States as Various Immunotherapies for:
- Melanoma
- Non-Hodgkin lymphoma
- Chronic myelogenous leukemia (CML)
- Kidney cancer
- Breast cancer
- Prostate cancer
- Bladder cancer
🇨🇦 Approved in Canada as Various Immunotherapies for:
- Melanoma
- Non-Hodgkin lymphoma
- Chronic myelogenous leukemia (CML)
- Kidney cancer
- Breast cancer
- Prostate cancer
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Johns Hopkins UniversityBaltimore, MD
Loading ...
Who Is Running the Clinical Trial?
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
Avon Breast Health Access FundCollaborator
Vanderbilt UniversityCollaborator
Bristol-Myers SquibbIndustry Sponsor